Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.
about
Dapagliflozin for type 2 diabetes mellitusSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseSpotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic reviewRisk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes MellitusSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinProximal nephronThe mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked?Mathematical modeling of renal tubular glucose absorption after glucose loadPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Old and new approaches to the interpretation of acid-base metabolism, starting from historical data applied to diabetic acidosis.Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.Maternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesThe Sweet Pee model for Sglt2 mutationEmpagliflozin in the treatment of type 2 diabetes: evidence to dateGlucose tolerance and left ventricular pressure-volume relationships in frequently used mouse strains.Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesThe baboon kidney transcriptome: analysis of transcript sequence, splice variants, and abundance.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsAngiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvationA computational approach to estimate interorgan metabolic transport in a mammal.Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibitionSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Multiorgan insulin sensitivity in lean and obese subjects.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateThe potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
P2860
Q24234557-667BFC75-6073-48BC-9DBA-4051731C7E95Q26752815-BA0DBE3D-7D27-4C56-BDBD-DAA81947F638Q26766404-0027C713-79C8-4BB5-92EE-80349FD2D1A0Q26777529-5368BDF7-E80F-4108-BA05-4484599F5B83Q27010669-504C6853-DE70-4E19-BAF5-3E979F2EB446Q28069065-11956152-96BC-410C-8613-97805AADFD68Q28071386-D6A5F392-65A0-4F38-8F57-456F4D383BCCQ28072980-6A6A2087-F6A6-4627-9E35-2577A85BB378Q28079134-98D11C91-30EB-4702-8B40-6EAE0847E61AQ28250844-E2C772C1-5D2E-480E-B790-1B4782D85C6DQ28388052-21DD7445-9E15-439B-AC83-775FDE1C53C1Q28396923-7AB3DFA0-5507-40FF-9C2F-484F7BAD82CFQ28539294-CD2D51EB-1BC7-4535-99F2-ACEFC64CE02FQ30597265-F7346BEE-29AE-4675-B8C2-022D40DEDC6FQ31114404-A17905D3-C637-4F59-9E79-053FC83ED44BQ33569169-0F0D3B85-4CEF-4D12-8E3F-85765D85632DQ33595643-A22AC842-87F6-4BC8-9281-AA3F311BE54EQ33696974-248C581F-DC47-4153-AB92-141924F6BCFAQ33837017-DE82D041-1713-4F31-8890-CFACAEA3DACDQ34105064-0FEE0666-728B-4AED-89ED-558AA82601CFQ34161881-D5F27CEE-F6EF-4650-8A5E-4684CA530AECQ34198692-0A944030-1A36-4236-A20E-1E5DBF925041Q34457273-E3F1480D-516D-4AB9-A5D9-81B8CFEBC6EDQ34502358-7972C418-6C24-4E07-A420-EB0F214BEE3AQ34557643-54EA52A0-D3B4-4B4B-9FC6-C3F4D57AE47DQ34635575-CF0F58E9-8428-4060-9878-626C128C8502Q34699217-899811CB-0840-44D1-A21D-E56EEC3D20DFQ34699867-62E05884-19EB-43BA-BF20-93F928CB6F0EQ34973750-F4658DAF-74C8-48AE-BB1E-20E6A9FDF9D0Q35105160-E16F9D86-0CBC-4ACE-AB06-CA3ED4E8CE00Q35196380-0955C1DC-F573-405C-96FD-04D4EAE7120CQ35225256-6AF54091-424F-4AA1-A028-6F0793043333Q35749639-96B752C4-545B-4D68-8FC6-C093E5C3299BQ35906490-08B4067D-03CB-4DCE-9628-91C944285817Q35976440-3AD33E9D-348E-48BB-AC0E-7DFF0475D919Q36059244-3A31B252-AA37-4124-A2F4-D8C6F530C617Q36257565-4298E98A-761B-451E-986E-245CB864F906Q36354599-7A1A213F-2960-48EB-B575-37A83415D892Q36435496-14ED30C6-FE2C-490E-A931-7A59E4B87110Q36592820-EAE15E5C-620A-4E88-9218-8CD18738C163
P2860
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Role of the kidney in normal g ...... tus: therapeutic implications.
@ast
Role of the kidney in normal g ...... tus: therapeutic implications.
@en
Role of the kidney in normal g ...... tus: therapeutic implications.
@nl
type
label
Role of the kidney in normal g ...... tus: therapeutic implications.
@ast
Role of the kidney in normal g ...... tus: therapeutic implications.
@en
Role of the kidney in normal g ...... tus: therapeutic implications.
@nl
prefLabel
Role of the kidney in normal g ...... tus: therapeutic implications.
@ast
Role of the kidney in normal g ...... tus: therapeutic implications.
@en
Role of the kidney in normal g ...... tus: therapeutic implications.
@nl
P2860
P921
P1433
P1476
Role of the kidney in normal g ...... tus: therapeutic implications.
@en
P2093
J E Gerich
P2860
P304
P356
10.1111/J.1464-5491.2009.02894.X
P577
2010-02-01T00:00:00Z